PP2A inhibition results in hepatic insulin resistance despite Akt2 activation

Aging

Volumn 5, Issue 10, 2013, Pages 770-781

  Galbo, Thomas ^a,b,c   Perry, Rachel J ^a   Nishimura, Erica ^b   Samuel, Varman T ^a,d   Quistorff, Bjørn ^c   Shulman, Gerald I ^a,b,e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Akt; Glucose metabolism; Insulin resistance; PP2A

Indexed keywords

AKT2 PROTEIN, RAT; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, RAT; GLYCOGEN; NERVE PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; PROTEIN KINASE B;

ANIMAL; ARTICLE; BIOSYNTHESIS; DRUG ANTAGONISM; ENZYME ACTIVATION; GLUCONEOGENESIS; INSULIN RESISTANCE; LIVER; MALE; METABOLISM; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ENZYME ACTIVATION; FORKHEAD TRANSCRIPTION FACTORS; GLUCONEOGENESIS; GLYCOGEN; INSULIN RESISTANCE; LIVER; MALE; NERVE TISSUE PROTEINS; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84886730615     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100611     Document Type: Article

References (41)

1. Samuel VT and Shulman GI. Mechanisms for insulin resistance:common threads and missing links. Cell. 2012;148:852-871.
2. Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes:implications for therapy. Diabetes. 2010;59:2697-2707.
3. Basu R, Schwenk WF and Rizza RA. Both fasting glucose production and disappearance are abnormal in people with "mild"and "severe"type 2 diabetes. American journal of physiology Endocrinology and metabolism. 2004;287:E55-62.
4. Petersen KF, Laurent D, Rothman DL, Cline GW and Shulman GI. Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. The Journal of clinical investigation. 1998;101:1203-1209.
5. Taniguchi CM, Emanuelli B and Kahn CR. Critical nodes in signalling pathways:insights into insulin action. Nature reviews Molecular cell biology. 2006;7:85-96.
6. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, 3rd, Kaestner KH, Bartolomei MS, Shulman GI and Birnbaum MJ. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 2001;292:1728-1731.
7. Puigserver P, Rhee J, Donovan J, Walkey CJ, Yoon JC, Oriente F, Kitamura Y, Altomonte J, Dong H, Accili D and Spiegelman BM. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature. 2003;423:550-555.
8. Matsumoto M, Pocai A, Rossetti L, Depinho RA and Accili D. Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell metabolism. 2007;6:208-216.
9. Matsuzaki H, Daitoku H, Hatta M, Tanaka K and Fukamizu A. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:11285-11290.
10. Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785-789.
11. Mistafa O, Ghalali A, Kadekar S, Hogberg J and Stenius U. Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatases. The Journal of biological chemistry. 2010;285:27900-27910.
12. Andjelkovic M, Jakubowicz T, Cron P, Ming XF, Han JW and Hemmings BA. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 1996;93:5699-5704.
13. Mumby M. The 3D structure of protein phosphatase 2A:new insights into a ubiquitous regulator of cell signaling. ACS chemical biology. 2007;2:99-103.
14. Cazzolli R, Carpenter L, Biden TJ and Schmitz-Peiffer C. A role for protein phosphatase 2A-like activity, but not atypical protein kinase Czeta, in the inhibition of protein kinase B/Akt and glycogen synthesis by palmitate. Diabetes. 2001;50:2210-2218.
15. Stratford S, Hoehn KL, Liu F and Summers SA. Regulation of insulin action by ceramide:dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. The Journal of biological chemistry. 2004;279:36608-36615.
16. Galbo T, Olsen GS, Quistorff B and Nishimura E. Free fatty acid-induced PP2A hyperactivity selectively impairs hepatic insulin action on glucose metabolism. PloS one. 2011;6:e27424.
17. Chavez JA and Summers SA. A ceramide-centric view of insulin resistance. Cell metabolism. 2012;15:585-594.
18. Ugi S, Imamura T, Maegawa H, Egawa K, Yoshizaki T, Shi K, Obata T, Ebina Y, Kashiwagi A and Olefsky JM. Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3T3-L1 adipocytes. Molecular and cellular biology. 2004;24:8778-8789.
19. Honkanen RE. Cantharidin, another natural toxin that inhibits the activity of serine/threonine protein phosphatases types 1 and 2A. FEBS letters. 1993;330:283-286.
20. Li YM and Casida JE. Cantharidin-binding protein:identification as protein phosphatase 2A. Proceedings of the National Academy of Sciences of the United States of America. 1992;89:11867-11870.
21. Lu J, Kovach JS, Johnson F, Chiang J, Hodes R, Lonser R and Zhuang Z. Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:11697-11702.
22. Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ and Storlien LH. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes. 1991;40:1397-1403.
23. Schaffer L, Brand CL, Hansen BF, Ribel U, Shaw AC, Slaaby R and Sturis J. A novel high-affinity peptide antagonist to the insulin receptor. Biochemical and biophysical research communications. 2008;376:380-383.
24. Huang H and Tindall DJ. Regulation of FOXO protein stability via ubiquitination and proteasome degradation. Biochimica et biophysica acta. 2011;1813:1961-1964.
25. Ingebritsen TS and Cohen P. Protein phosphatases:properties and role in cellular regulation. Science. 1983;221:331-338.
26. Ingebritsen TS, Stewart AA and Cohen P. The protein phosphatases involved in cellular regulation. 6. Measurement of type-1 and type-2 protein phosphatases in extracts of mammalian tissues;an assessment of their physiological roles. European journal of biochemistry/FEBS. 1983;132:297-307.
27. Bollen M, Keppens S and Stalmans W. Specific features of glycogen metabolism in the liver. The Biochemical journal. 1998;336:19-31.
28. Kahn BB, Alquier T, Carling D and Hardie DG. AMP-activated protein kinase:ancient energy gauge provides clues to modern understanding of metabolism. Cell metabolism. 2005;1:15-25.
29. Dong XC, Copps KD, Guo S, Li Y, Kollipara R, DePinho RA and White MF. Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation. Cell metabolism. 2008;8:65-76.
30. Lu M, Wan M, Leavens KF, Chu Q, Monks BR, Fernandez S, Ahima RS, Ueki K, Kahn CR and Birnbaum MJ. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nature medicine. 2012;18:388-395.
31. Aiston S, Coghlan MP and Agius L. Inactivation of phosphorylase is a major component of the mechanism by which insulin stimulates hepatic glycogen synthesis. European journal of biochemistry/FEBS. 2003;270:2773-2781.
32. Ramnanan CJ, Edgerton DS, Rivera N, Irimia-Dominguez J, Farmer B, Neal DW, Lautz M, Donahue EP, Meyer CM, Roach PJ and Cherrington AD. Molecular characterization of insulinmediated suppression of hepatic glucose production in vivo. Diabetes. 2010;59:1302-1311.
33. Kowluru A and Matti A. Hyperactivation of protein phosphatase 2A in models of glucolipotoxicity and diabetes:Potential mechanisms and functional consequences. Biochemical pharmacology. 2012;84:591-597.
34. Liangpunsakul S, Sozio MS, Shin E, Zhao Z, Xu Y, Ross RA, Zeng Y and Crabb DW. Inhibitory effect of ethanol on AMPK phosphorylation is mediated in part through elevated ceramide levels. American journal of physiology Gastrointestinal and liver physiology. 2010;298:G1004-1012.
35. Kabashima T, Kawaguchi T, Wadzinski BE and Uyeda K. Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:5107-5112.
36. Kawaguchi T, Takenoshita M, Kabashima T and Uyeda K. Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation/dephosphorylation of the carbohydrate response element binding protein. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:13710-13715.
37. Wu Y, Song P, Xu J, Zhang M and Zou MH. Activation of protein phosphatase 2A by palmitate inhibits AMP-activated protein kinase. The Journal of biological chemistry. 2007;282:9777-9788.
38. Gotz J and Schild A. Transgenic and knockout models of PP2A. Methods in enzymology. 2003;366:390-403.
39. Seglen PO. Preparation of isolated rat liver cells. Methods in cell biology. 1976;13:29-83.
40. Lowry OH and Passonneau JV. (1972). A flexible system of enzymatic analysis. (New York,:Academic Press).
41. Rossetti L, Smith D, Shulman GI, Papachristou D and DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. The Journal of clinical investigation. 1987;79:1510-1515.